Abstract:Despite the successful use of the radiopharmaceutical radium-223 dichloride ([ 223 Ra]RaCl 2 ) for targeted alpha therapy of castration-resistant prostate cancer patients with bone metastases, some short-term side effects, such as diarrhea and vomiting, have been documented, causing patient discomfort. Hence, we prepared a nanosized micellar solution of [ 223 Ra]RaCl 2 and evaluated its biodistribution, pharmacokinetics, and induced biochemical changes in healthy mice up to 96 hours after intraperitoneal administration as an alternative to overcome the previous limitations. In addition, we evaluated the bone specificity of micellar [ 223 Ra]RaCl 2 in patient-derived xenografts in the osteosarcoma model. The biodistribution studies revealed the high bone-targeting properties of the micellar [ 223 Ra]RaCl 2 . Interestingly, the liver uptake remained significantly low (%ID/g = 0.1 - 0.02) from 24 to 96 hours after administration. In addition, the micellar [ 223 Ra]RaCl 2 exhibited a significantly higher uptake in left (%ID/g = 0.85 - 0.23) and right (%ID/g = 0.76 - 0.24) kidneys than in small (%ID/g = 0.43 - 0.06) and large intestines (%ID/g = 0.24 - 0.09) over time, suggesting its excretion pathway is primarily through the kidneys into the urine, in contrast to the non-micellar [ 223 Ra]RaCl 2 . The micellar [ 223 Ra]RaCl 2 also had low distribution volume (0.055 ± 0.003 L) and longer elimination half-life (28 ± 12 days). This nanosystem was unable to change the enzymatic activities of alanine aminotransferase, aspartate aminotransferase, gamma GT, glucose, and liquiform lipase in the treated mice. Finally, microscopic examination of the animals' osteosarcoma tumors treated with micellar [ 223 Ra]RaCl 2 indicated regression of the tumor, with large areas of necrosis. In contrast, in the control group, we observed tumor cellularity and cell anaplasia, mitotic figures and formation of neoplastic extracellular bone matrix, which are typical features of osteosarcoma. Therefore, our findings demonstrated the efficiency and safety of nanosized micellar formulations to minimize the gastrointestinal excretion pathway of the clinical radiopharmaceutical [ 223 Ra]RaCl 2 , in addition to promoting regression of the osteosarcoma. Further studies must be performed to assess dose-response outcomes and organ/tissue dosimetry for clinical translation.

[ 223 Ra] RaCl 2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era

Micellar Solution of [ 223 Ra]RaCl 2 : Reaching renal excretion, Potent Efficacy in Osteoblastic Osteosarcoma in PDX Model, Biochemistry Alterations and Pharmacokinetics

Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results

Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration-resistant prostate cancer and bone metastases

Navigating through the coordination preferences of heavy alkaline earth metals: Laying the foundations for 223 Ra- and 131/135m Ba-based targeted alpha therapy and theranostics of cancer

Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer

A Sodium Alginate Intervention Strategy to Enhance Therapeutic Effects of Bone-Targeted Alpha Therapy Via Remodeling 223racl2 Distribution.

Radium 223 dichloride for prostate cancer treatment

Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer

Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis

Development in the Study of Radium-223 Chloride for Treating Castration-Resistant Prostate Carcinoma with Bone Metastases

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies

Biomarkers of bone metabolism in [223Ra] RaCl2 therapy - association with extent of disease and prediction of overall survival

Enhancing 223ra Treatment Efficacy by Anti-β1 Integrin Targeting.

Clinical experience of using the radium-223 in patients with bone metastasis of castration-resistant prostate cancer

D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters

Targeted Alpha Anticancer Therapies: Update and Future Prospects.

Engineering Mesoporous Silica Nanoparticles for Targeted Alpha Therapy against Breast Cancer

Using a Hybrid Radioenhancer to Discover Tumor Cell-targeted Treatment for Osteosarcoma: An In Vitro Study

Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials